Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This randomized phase II trial is to see if combination chemotherapy works better with or
without bevacizumab in treating patients who have malignant mesothelioma. Drugs used in
chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or
die. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways.
Some block the ability of cancer cells to grow and spread. Others find cancer cells and help
kill them or deliver cancer-killing substances to them. It is not yet known if combination
chemotherapy works better with or without bevacizumab in treating malignant mesothelioma.